RESUMO
The COVID-19 pandemic led to a decrease in the number of operating rooms available. Single-stage islanded forehead flaps have emerged as a good alternative to the classic frontal flap helping to diminish the surgical waiting list. We present our case series of 6 patients reconstructed with islanded forehead flaps between February and July 2020.The purpose of this report is to assess the advantages and disadvantages of this technique in order to inform which subgroup of patients may benefit from the one-stage flap, now the pandemic is better controlled.
Assuntos
COVID-19 , Rinoplastia , Testa , Humanos , Nariz/cirurgia , Pandemias , Rinoplastia/métodosRESUMO
Topical immunotherapy with dyphencyprone (DPCP) is widely used in patients with alopecia areata (AA). It can produce a contact dermatitis that is believed to decrease Th1 response, predominant in AA. It has been shown that imiquimod (IMQ), a topical immunomodulator drug, can produce sensitization to DPCP in patients that do not show signs of contact dermatitis when exposed to DPCP. Nevertheless, there is no evidence as to whether it can improve DPCP efficacy in already sensitized patients. We present a series of 9 patients, (7 females [77%] and 2 males [22%]) with a mean age of 38.4 years (range, 19-60 years), successfully sensitized to DPCP, that were treated with a combination of DPCP and IMQ. The mean SALT (Severity of Alopecia Tool) score before adding IMQ was 43.3 (range, 10-60), and the mean number of months of DPCP use prior to the addition of IMQ was 6.8 (range 0-10). After adding IMQ to their DPCP treatment, 77% of the patients had further improvement, with a mean SALT reduction of 13.3 (range, [-50] - 40), and a mean duration of response of 5.2 months. No adverse effects were reported. According to this data, we believe that the combination of DPCP and IMQ can be a promising way of improving the efficacy of contact immunotherapy in AA, and requires further study.
Assuntos
Alopecia em Áreas , Dermatite de Contato , Adulto , Alopecia em Áreas/induzido quimicamente , Alopecia em Áreas/tratamento farmacológico , Ciclopropanos , Feminino , Cabelo , Humanos , Imiquimode/uso terapêutico , Fatores Imunológicos , Imunoterapia/efeitos adversos , Masculino , Resultado do TratamentoRESUMO
A woman presented to the emergency department during the COVID-19 pandemic, reporting a slightly pruritic rash that had developed five days after the onset of fever, cough and malaise.
Assuntos
COVID-19 , Exantema , Exantema/etiologia , Feminino , Febre/etiologia , Humanos , Pandemias , SARS-CoV-2Assuntos
Púrpura , Dermatopatias Vasculares , Meios de Cultura , Humanos , Púrpura/induzido quimicamenteRESUMO
Acute telogen effluvium has been recognised as a dermatological sequela of COVID-19.
